Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
Sign Up to like & getrecommendations! Published in 2018 at "CNS Drugs"
DOI: 10.1007/s40263-018-0586-5
Abstract: BackgroundWalking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one… read more here.
Keywords: improvement; multiple sclerosis; placebo; clinically meaningful ... See more keywords
Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical biomechanics"
DOI: 10.1016/j.clinbiomech.2021.105382
Abstract: BACKGROUND People with multiple sclerosis have reduced walking speed and impaired gait pattern. Prolonged release-fampridine is a potassium channel blocker that improves nerve conduction in patients with multiple sclerosis, leading to walking benefits. Whether fampridine… read more here.
Keywords: prolonged release; multiple sclerosis; fampridine; release fampridine ... See more keywords
Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the Neurological Sciences"
DOI: 10.1016/j.jns.2020.116978
Abstract: Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. Associated fampridine-induced changes in the walking pattern are still poorly understood but may provide… read more here.
Keywords: induced changes; fampridine induced; changes walking; multiple sclerosis ... See more keywords
Experience with fampridine in clinical practice: analysis of a possible marker of clinical response
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Neuroscience"
DOI: 10.1080/00207454.2017.1279614
Abstract: ABSTRACT Purpose of the study: Approximately 85% of patients with multiple sclerosis experience reduced mobility, which negatively affects quality of life. Fampridine is the first symptomatic treatment aimed at improving gait. We analyzed effectiveness and… read more here.
Keywords: response; clinical practice; pattern; gait ... See more keywords